SCHEMBL4236340

SCHEMBL4236340

[CH2]On1c(C)c(C)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 4/20 0.40
GPR3 P46089 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 2/20 0.35
LMNA P02545 1/20 0.35
ALOX15 P16050 1/20 0.35
MAPT P10636 4/20 0.35
GRIK2 Q13002 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC10 Q969S8 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
GAA P10253 2/20 0.33
CYP2C19 P33261 2/20 0.33
IDO1 P14902 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236344 0.82 SMN1; SMN2 (0.47) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10
SCHEMBL3972584 0.72 KDM4E (0.44) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10
SCHEMBL31132408 0.70 GPR3 (0.61) KDM4EALDH1A1GPR3HSD17B10MAPT
SCHEMBL483003 0.70 GPR3 (0.61) KDM4EALDH1A1GPR3HSD17B10MAPT
SCHEMBL19201062 0.68 KDM4E (0.44) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10
SCHEMBL21653639 0.68 KDM4E (0.44) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10
SCHEMBL28164947 0.68 KDM4E (0.44) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10
SCHEMBL3220620 0.68 KDM4E (0.44) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10
Bromide SCHEMBL15569971 0.68 GPR3 (0.58) KDM4EALDH1A1GPR3HSD17B10MAPT
SCHEMBL27925001 0.68 KDM4E (0.44) KDM4EALDH1A1GPR3SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 KDM4E 2397/4885ALDH1A1 839/4885GPR3 3290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.